EVOLUS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
EVOLUS, INC. (EOLS) reported Increase (Decrease) in Prepaid Expense and Other Assets of $7.26 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2022-03-03
- EVOLUS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2020-12-31 was $1.01M, a 42.92% increase year-over-year.
- EVOLUS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2020-09-30 was $1.75M.
- EVOLUS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2020-06-30 was $697.00K, a 100.29% increase year-over-year.
- EVOLUS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2020-03-31 was -$1.77M, a 207.40% decline year-over-year.
- EVOLUS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2021 was $7.26M, a 329.82% increase from fiscal 2020.
- EVOLUS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2020 was $1.69M, a 9.82% decline from fiscal 2019.
- EVOLUS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2019 was $1.87M, a 88.91% increase from fiscal 2018.
- EVOLUS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2018 was $992.00K, a 520.00% increase from fiscal 2017.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $7.26M 10-K · filed 2022-03-03 | ||||
| 2020-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $2.76M derived: sum of 2 quarters · filed 2022-03-03 | $3.46M derived: sum of 3 quarters · filed 2022-03-03 | $1.69M 10-K · filed 2022-03-03 | |
| 2020-09-30 | $1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $2.45M derived: sum of 2 quarters · filed 2020-10-29 | $681.00K 10-Q · filed 2020-10-29 | $1.39M derived: sum of 4 quarters · filed 2021-03-25 | |
| 2020-06-30 | $697.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$1.07M 10-Q · filed 2020-08-10 | -$368.00K derived: sum of 3 quarters · filed 2021-03-25 | -$1.20M derived: sum of 4 quarters · filed 2021-03-25 | |
| 2020-03-31 | -$1.77M 10-Q · filed 2020-05-11 | -$1.06M derived: sum of 2 quarters · filed 2021-03-25 | -$1.89M derived: sum of 3 quarters · filed 2021-03-25 | -$1.55M derived: sum of 4 quarters · filed 2021-03-25 | |
| 2019-12-31 | $706.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$123.00K derived: sum of 2 quarters · filed 2021-03-25 | $225.00K derived: sum of 3 quarters · filed 2021-03-25 | $1.87M 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$829.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | -$481.00K derived: sum of 2 quarters · filed 2020-10-29 | $1.17M 10-Q · filed 2020-10-29 | $1.41M 10-Q · filed 2019-11-04 | $1.42M derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-06-30 | $348.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $2.00M 10-Q · filed 2020-08-10 | $2.25M derived: sum of 3 quarters · filed 2020-08-10 | $2.13M derived: sum of 4 quarters · filed 2020-08-10 | |
| 2019-03-31 | $1.65M 10-Q · filed 2020-05-11 | $1.90M derived: sum of 2 quarters · filed 2020-05-11 | $1.79M derived: sum of 3 quarters · filed 2020-05-11 | $2.29M derived: sum of 4 quarters · filed 2020-05-11 | |
| 2018-12-31 | $253.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $138.00K derived: sum of 2 quarters · filed 2020-02-25 | $636.00K derived: sum of 3 quarters · filed 2020-02-25 | $992.00K 10-K · filed 2020-02-25 | |
| 2018-09-30 | -$115.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $383.00K derived: sum of 2 quarters · filed 2019-11-04 | $739.00K 10-Q · filed 2019-11-04 | $634.00K derived: sum of 4 quarters · filed 2019-11-04 | |
| 2018-06-30 | $498.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $854.00K 10-Q · filed 2019-08-12 | $749.00K derived: sum of 3 quarters · filed 2019-08-12 | $925.00K derived: sum of 4 quarters · filed 2019-08-12 | |
| 2018-03-31 | $356.00K 10-Q · filed 2019-05-01 | $251.00K derived: sum of 2 quarters · filed 2019-05-01 | $427.00K derived: sum of 3 quarters · filed 2019-05-01 | $519.00K derived: sum of 4 quarters · filed 2019-05-01 | |
| 2017-12-31 | -$105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-20 | $71.00K derived: sum of 2 quarters · filed 2019-03-20 | $163.00K derived: sum of 3 quarters · filed 2019-03-20 | $160.00K 10-K · filed 2019-03-20 | |
| 2017-09-30 | $176.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $268.00K derived: sum of 2 quarters · filed 2018-11-05 | $265.00K 10-Q · filed 2018-11-05 | ||
| 2017-06-30 | $92.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $89.00K 10-Q · filed 2018-08-02 | |||
| 2017-03-31 | -$3.00K 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |